CONTACT US

Investor Relations Resource Center

From the Frontlines of Healthcare IR

We're sharing insights from our experienced team of data-driven industry leaders in healthcare investor relations and external communications. Check back for new monthly newsletters, video interviews, and other free offerings to help you reach your financing goals. 

Insights & Updates from our leadership team

Our people work hard, and they do it together.

What We’re Doing

Driving biopharma brand success with benchmarking insights and collaborative action

Driving biopharma brand success with benchmarking insights and collaborative action

Pauline Schöller | Senior Strategy Consultant, Precision AQ | 19 May 2025

June 6, 2025

Why Cardiovascular-Kidney-Metabolic (CKM) Health Is a Top Priority for Payers—and What It Means for Manufacturers

Why Cardiovascular-Kidney-Metabolic (CKM) Health Is a Top Priority for Payers—and What It Means for Manufacturers

Cynthia Miller, MD, MPH, FACP | VP, Medical Director, Access Experience Team Christopher Terrone | VP, Healthcare...

June 3, 2025

Meet Our Access Experience Team: Shraddha Kansagra, PharmD, BCOP

Meet Our Access Experience Team: Shraddha Kansagra, PharmD, BCOP

At Precision AQ, we know that navigating patient access challenges requires more than data—it takes real-world...

June 2, 2025

Sign up for the newsletter

Access to the Best and Brightest: Video Interview Series

Precision Bioscience

To kick off the year at the Precision AQ Corporate Access event in San Francisco, Precision AQ EVP & Managing Director, Hannah Deresiewicz, sat down with Precision BioSciences, Inc. CFO Alex Kelly. They discussed the company's proprietary ARCUS® in vivo gene editing platform and its Phase 1 ELIMINATE-B trial for chronic hepatitis B, which recently announced initial safety and substantial antiviral activity in the first cohort of patients after first administration of PBGENE-HBV. 

ProMIS Neurosciences

ProMIS Neurosciences CEO, Neil Warma, sat down with Precision AQ EVP & Managing Director, Hannah Deresiewicz, during the Precision AQ Corporate Access Event in San Francisco. They talked about the Alzheimer’s disease landscape and the progress of ProMIS’ lead candidate, PMN310.

Reunion

Reunion Neuroscience’s CEO Greg Mayes sat down with Precision AQ EVP & Managing Director, Hannah Deresiewicz at the J.P. Morgan Healthcare Conference earlier this year. They discussed the company’s efforts to revolutionize the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions.

Spur Therapeutics

This January in San Francisco, Precision AQ EVP & Managing Director Hannah Deresiewicz sat down with Spur Therapeutics CEO Michael Parini at the J.P. Morgan Healthcare Conference. They discussed how Spur is pushing the boundaries of gene therapy through a redefined approach of developing gene therapies for treatment of serious chronic diseases.

Resolution

Resolution Therapeutics CEO, Amir Hefni, sat down with Precision AQ EVP & Managing Director, Hannah Deresiewicz, during the Precision AQ Corporate Access Event San Francisco. They highlighted the company’s latest progress in their lead asset RTX001, a Regenerative Macrophage Therapy for end-stage liver disease.

Esperion

Esperion CEO, Sheldon Koenig, sat down with Precision AQ EVP & Managing Director, Hannah Deresiewicz, during the Precision AQ Corporate Access Event last month in San Francisco. They talked about Esperion’s progress advancing innovative medicines that help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. 

Discover the New Blueprint for Access with Precision AQ